PE20010347A1 - Agonistas y antagonistas de estrogenos para indicaciones multiples - Google Patents
Agonistas y antagonistas de estrogenos para indicaciones multiplesInfo
- Publication number
- PE20010347A1 PE20010347A1 PE2000000737A PE0007372000A PE20010347A1 PE 20010347 A1 PE20010347 A1 PE 20010347A1 PE 2000000737 A PE2000000737 A PE 2000000737A PE 0007372000 A PE0007372000 A PE 0007372000A PE 20010347 A1 PE20010347 A1 PE 20010347A1
- Authority
- PE
- Peru
- Prior art keywords
- antagonists
- estrogen agonists
- multiple indications
- phenyl
- indications
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
SE REFIERE AL USO DE MODULADORES SELECTIVOS DEL RECEPTOR DE ESTROGENO TAL COMO LASOFOXIFENO ((-)-CIS-6-FENIL-5-[4-(2-PIRROLIDIN-1-IL-ETOXI)-FENIL]-5,6,7,8-TERTRAHIDRONAFTALEN-2-OL); DROLOXIFENO PARA EL TRATAMIENTO DE LA OSTEOPOROSIS, ENFERMEDAD CARDIOVASCULAR, CANCER DE MAMA SIN INTERFERIR CON LA ACCION DE WARFARINA O PROPANOLOL
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14607299P | 1999-07-28 | 1999-07-28 | |
US14607599P | 1999-07-28 | 1999-07-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20010347A1 true PE20010347A1 (es) | 2001-03-23 |
Family
ID=26843545
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2000000737A PE20010347A1 (es) | 1999-07-28 | 2000-07-21 | Agonistas y antagonistas de estrogenos para indicaciones multiples |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP1086692A3 (es) |
JP (1) | JP2001048805A (es) |
KR (1) | KR20010049909A (es) |
AU (1) | AU4882700A (es) |
CA (1) | CA2314572A1 (es) |
HU (1) | HUP0002979A2 (es) |
IL (1) | IL137428A0 (es) |
NZ (1) | NZ506014A (es) |
PE (1) | PE20010347A1 (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6436977B1 (en) * | 1999-09-29 | 2002-08-20 | Pfizer Inc. | Dosing regimens for lasofoxifene |
GB2475907A (en) * | 2009-12-04 | 2011-06-08 | Tcp Innovations Ltd | Composition comprising a mixture of clopidogrel and droloxifene |
US20190231743A1 (en) * | 2016-10-11 | 2019-08-01 | Sermonix Pharmaceuticals, Llc | Lasofoxifene treatment of vva and osteoporosis in survivors of breast cancer and other malignancies |
EP3525774B1 (en) | 2016-10-11 | 2021-12-29 | Duke University | Lasofoxifene treatment of er+ breast cancer |
CN117771239A (zh) | 2018-04-10 | 2024-03-29 | 杜克大学 | 乳腺癌的拉索昔芬治疗 |
GB202116903D0 (en) | 2021-11-18 | 2022-01-05 | Sermonix Pharmaceuticals Inc | Lasofoxifene treatment of aromatase-resistant er+ cancer |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5552412A (en) * | 1995-01-09 | 1996-09-03 | Pfizer Inc | 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis |
-
2000
- 2000-07-03 EP EP00305611A patent/EP1086692A3/en not_active Withdrawn
- 2000-07-20 IL IL13742800A patent/IL137428A0/xx unknown
- 2000-07-21 PE PE2000000737A patent/PE20010347A1/es not_active Application Discontinuation
- 2000-07-24 JP JP2000222159A patent/JP2001048805A/ja active Pending
- 2000-07-25 AU AU48827/00A patent/AU4882700A/en not_active Abandoned
- 2000-07-26 CA CA002314572A patent/CA2314572A1/en not_active Abandoned
- 2000-07-27 KR KR1020000043433A patent/KR20010049909A/ko not_active Application Discontinuation
- 2000-07-27 NZ NZ506014A patent/NZ506014A/en unknown
- 2000-07-27 HU HU0002979A patent/HUP0002979A2/hu unknown
Also Published As
Publication number | Publication date |
---|---|
NZ506014A (en) | 2001-11-30 |
HUP0002979A2 (hu) | 2002-04-29 |
KR20010049909A (ko) | 2001-06-15 |
EP1086692A2 (en) | 2001-03-28 |
EP1086692A3 (en) | 2003-07-09 |
IL137428A0 (en) | 2001-07-24 |
AU4882700A (en) | 2001-02-01 |
CA2314572A1 (en) | 2001-01-28 |
JP2001048805A (ja) | 2001-02-20 |
HU0002979D0 (en) | 2000-10-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2172579T3 (es) | Agonistas/antagonistas de estrogenos. | |
PA8548901A1 (es) | Ligandos del receptor 5-ht y sus usos | |
ECSP077233A (es) | Moduladores del receptor de progesterona que comprenden los derivados del pirrol-oxindol y los usos de los mismos | |
ECSP066773A (es) | Intermediarios de quinolina como inhibidores de receptores de tirosina quinasas y la síntesis de los mismos | |
UY26974A1 (es) | Agonistas del receptor beta3 adrenérgico y usos de los mismos | |
AR028824A1 (es) | Compuestos antagonistas npy-5 y su uso en la manufactura de medicamentos. | |
PA8638701A1 (es) | Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos | |
CL2015002098A1 (es) | “compuestos derivados de benzotiofeno, antagonistas de receptores de estrógenos y degradantes selectivos de éstos (sreds); composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer de mamas, ovarios, endometrial, próstata, uterino, cervical y pulmones”. pct | |
UY28766A1 (es) | Compuestos heteropolicíclicos adicionales y su uso como antagonistas del receptor de glutamato metabotrópico | |
ECSP003531A (es) | Derivados de purina | |
ECSP003713A (es) | Derivados de purina | |
ECSP034428A (es) | Ciclopentanoindoles, composiciones conteniendo tales compuestos y su uso | |
ECSP066856A (es) | Compuestos novedosos como moduladores del receptor opioide | |
UY27760A1 (es) | Nuevos derivados de pirrolidinio. | |
HN1998000157A (es) | Agonistas de prostaglandinas | |
UY28731A1 (es) | Compuestos quimicos | |
MY155036A (en) | Quinolinone-carboxamide compounds as 5-ht4 receptor agonists | |
ECSP088584A (es) | Nuevos derivados de benzimidazol como inhibidores del receptor vanilloide 1 (vrl) | |
UY28870A1 (es) | Derivados heterocíclicos, composiciones y proceso de preparación | |
EA200700367A1 (ru) | Новые производные 4-бензилиденпиперидина | |
PE20010347A1 (es) | Agonistas y antagonistas de estrogenos para indicaciones multiples | |
ECSP034860A (es) | 5-sustituidas-2-arilpiridinas como moduladores del factor 1 de liberación de corticotropina | |
ECSP11011428A (es) | Antagonistas del receptor tipo toll 3 | |
PT1355639E (pt) | Derivados de carboestirilo substituidos como agonistas do subtipo de receptores 5-ht1a | |
ECSP088603A (es) | Nuevas n-(fluor-pirazinil)-fenilsulfonamidas como moduladores del receptor de quimioquina ccr4 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |